扶正化毒方维持治疗中晚期化疗后非小细胞肺癌43例

黄炳辉; 查青林; 周智

doi:10.13422/j.cnki.syfix.2014080210

您当前的位置：

首页 >

文章列表页 >

扶正化毒方维持治疗中晚期化疗后非小细胞肺癌43例

更新时间：2024-01-04

- 扶正化毒方维持治疗中晚期化疗后非小细胞肺癌43例
- Fuzheng Huadu Decoction Maintenance Therapy in Advanced Non Small Cell Lung Cancer after Chemotherapy in 43 Cases
- 中国实验方剂学杂志 2014年20卷第8期页码：210-213
- 作者机构：
- 作者简介：
- 基金信息：
  
  江西省中医药管理局科技计划项目（20110527）
- DOI：10.13422/j.cnki.syfix.2014080210
  中图分类号：
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
黄炳辉, 查青林, 周智. 扶正化毒方维持治疗中晚期化疗后非小细胞肺癌43例[J]. 中国实验方剂学杂志, 2014,20(8):210-213.

HUANG Bing-hui, ZHA Qing-lin, ZHOU Zhi. Fuzheng Huadu Decoction Maintenance Therapy in Advanced Non Small Cell Lung Cancer after Chemotherapy in 43 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 210-213.
黄炳辉, 查青林, 周智. 扶正化毒方维持治疗中晚期化疗后非小细胞肺癌43例[J]. 中国实验方剂学杂志, 2014,20(8):210-213. DOI： 10.13422/j.cnki.syfix.2014080210.

HUANG Bing-hui, ZHA Qing-lin, ZHOU Zhi. Fuzheng Huadu Decoction Maintenance Therapy in Advanced Non Small Cell Lung Cancer after Chemotherapy in 43 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 210-213. DOI： 10.13422/j.cnki.syfix.2014080210.

摘要

目的：探讨扶正化毒方维持治疗对中晚期非小细胞肺癌（NSCLC）化疗患者生活质量及无进展生存期的影响。方法：将85例中晚期NSCLC患者随机按入院顺序分为对照组42例和观察组各43例。对照组进行对症支持治疗，观察组在对照组治疗的基础上加用扶正化毒方。两组患者直至出现病情进展后终止观察。采用欧洲癌症研究和治疗组织生命质量核心量表（EORTCQLQ-C30）；进行治疗前后KPS评分；记录无进展生存期（PFS）；检测治疗前后T细胞亚群（CD4+，CD4+，CD8+，CD4+/CD8+）和免疫球蛋白检测（IgG，IgA，IgM）。结果：治疗后观察组躯体功能、角色功能、情绪功能、社会功能和整体生活质量评分均好于对照组（P<0.01）；观察组在疲倦、恶心与呕吐、呼吸困难、失眠、食欲丧失维度评分低于对照组（P<0.01）；观察组KPS评分提高+稳定率为90.70%，优于对照组的71.43%（P<0.05）；观察组无进展生存期（7.3±0.85）个月优于对照组的（4.5±1.08）个月（P<0.01）；治疗后观察组CD3+，CD4+，CD4+/CD8+和IgG均较治疗前升高，并高于对照组（P<0.01）。结论：扶正化毒方维持治疗能提高化疗后中晚期非小细胞肺癌（NSCLC）患者的生存质量，延长无进展生存期（PFS），调节免疫功能。

Abstract

Objective: The discuss the influence on patients' living quality and progression free survival of Fuzheng Huadu decoction to treat non-small cell lung cancer(NSCLC) in the middle and late period after chemotherapy. Method: Eighty-five cases of patients with NSCLC were randomly divided into control group (42 cases) and observation group (43 cases)according to hospital admission order.The patients in control group used symptomatic and supportive treatment.The patients in the observation group plus Fuzheng Huadu decoction on the basis of control group treatment. Until their disease appeared terminate the observation.Adopt European organization research and treatment of cancer quality of life(EORTCQLQ-C30).Conduct therapy KPS grade.Record progression free survival(PFS).Detect T cell subset (CD3+

CD4+

CD8+

CD4+/CD8+)and lmmunoglobulin detection(IgG

IgA

IgM). Result: After treatment

for the observation group the scores of physical performance

role function

emotional function

society function and global quality of life were superior to that of the control group(P<0.01). As for the scores of tired

nausea and vomit

dyspnea

insomnia and the loss of appetite were lower than that of the control group(P<0.01). Karnofsky rate (increasing+stable) was 90.70% superior to 71.43% of the control group71.43%(P<0.05). And the progression free survival of the observation group was (7.3±0.85)mouths superior to (4.5±1.08) of the control group(P<0.01). And compared with the index before treatment

CD3+

CD4+

CD8+

CD4+/CD8+ and IgG all improved which were higher than that of the control group(P<0.01). Conclusion: The maintenance treatment of Fuzheng Huadu decoction can improve the quality of life of patients when it was used in non small cell lung cancer

after chemotherapy and lengthen PFS

improve immune function.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

癌康宁合剂对晚期非小细胞肺癌化疗后患者维持治疗的临床评价

清燥救肺汤加减对晚期非小细胞肺癌化疗患者生活质量和生存期的影响

肺抑瘤合剂对中、晚期肺鳞状细胞癌预后的影响

解郁肝舒胶囊联合阿德福韦酯、联苯双酯治疗慢性乙型肝炎52例

绞股蓝抗癌方辨证同步化疗和维持治疗中晚期非小细胞肺癌的临床分析